| Item type |
☆紀要論文 / Departmental Bulletin Paper(1) |
| 公開日 |
2020-02-05 |
| タイトル |
|
|
タイトル |
<Original> Quality of life of chronic myelogenous leukemia patients following BCR-ABL inhibitor therapy: A multicenter study in Nara Japan using SF-8 |
|
言語 |
en |
| 著者 |
Hanamoto, Hitoshi
Fujimoto, Ko
Fujii, Aki
Fujita, Mariko
Iioka, Futoshi
Tanaka, Haruyuki
Yagi, Hideo
Akasaka, Takashi
Amano, Itsuto
Ohno, Hitoshi
Tsubaki, Kazuo
|
| 言語 |
|
|
言語 |
eng |
| キーワード |
|
|
主題 |
QOL, TKI, CML |
| 資源タイプ |
|
|
資源タイプ識別子 |
http://purl.org/coar/resource_type/c_6501 |
|
資源タイプ |
departmental bulletin paper |
| 著者 所属 |
|
|
値 |
Department of Hematology, Kindai University Nara Hospital |
| 著者 所属 |
|
|
値 |
Department of Hematology, Kindai University Nara Hospital |
| 著者 所属 |
|
|
値 |
Department of Hematology, Kindai University Nara Hospital |
| 著者 所属 |
|
|
値 |
Department of Hematology, Kindai University Nara Hospital |
| 著者 所属 |
|
|
値 |
Department of Hematology, Tenri Hospital |
| 著者 所属 |
|
|
値 |
Nara Medical University 2nd Dept. of Internal Medicine |
| 著者 所属 |
|
|
値 |
Department of Hematology and Oncology, Nara Prefecture General Medical Center |
| 著者 所属 |
|
|
値 |
Department of Hematology, Tenri Hospital |
| 著者 所属 |
|
|
値 |
Nara Medical University 2nd Dept. of Internal Medicine |
| 著者 所属 |
|
|
値 |
Department of Hematology, Tenri Hospital |
| 著者 所属 |
|
|
値 |
Japanese Red Cross Chugoku-Shikoku Block Blood Center |
| 版 |
|
|
出版タイプ |
NA |
|
出版タイプResource |
http://purl.org/coar/version/c_be7fb7dd8ff6fe43 |
| 出版者 名前 |
|
|
出版者 |
Kindai University Medical Association |
| 書誌情報 |
en : ACTA MEDICA KINDAI UNIVERSITY
巻 44,
号 2,
p. 25-31,
発行日 2019-12
|
| ISSN |
|
|
収録物識別子タイプ |
ISSN |
|
収録物識別子 |
03866092 |
| 抄録 |
|
|
内容記述タイプ |
Abstract |
|
内容記述 |
[Abstract] Chronic myelogenous leukemia (CML) is caused by chromosomal translocation t (9;22) (q34;q11.2) forming a BCR-ABL fusion gene. Treatment of CML patients with tyrosine kinase inhibitor (TKI) led to a marked improvement in the survival rate. However, when treating CML patients, adverse events of TKI may reduce the QOL. When we were able to use only Imatinib, we continued to use despite adverse events. However, we can now use Dasatinib, Nilotinib, Bosutinib, and Ponatinib. Therefore, to examine the effects of TKI on the QOL of CML patients, we conducted a QOL survey at three major facilities in Nara Prefecture. For the QOL survey, we used SF-8. The results of the survey showed that there was no difference between the pretreatment QOL score and QOL score at the time of the survey. However, the QOL scores showed improved physical functioning, bodily pain, vitality, role-emotional, and mental health summary scores in the TKI switch group. The main reason for switching TKI was adverse events. Therefore, these adverse events reduce the QOL of CML patients. Switching TKI improved the QOL. Presently, five TKI are available, expanding the range of options. When adverse events appear, switching TKI and adverse event management are also important to maintain a patient’s QOL and continue the therapy. |
| フォーマット |
|
|
内容記述タイプ |
Other |
|
内容記述 |
application/pdf |
AA0050842X-20191200-0025.pdf (399.3 kB)
